The present invention relates to a pharmaceutical composition for the prevention or treatment of bone disease comprising, as an active ingredient, a parathyroid hormone (PTH) or a fusion peptide in which a bone tissue selection peptide is bound to a section thereof, more specifically, a sequence The present invention relates to a pharmaceutical composition and biomaterial for bone disease prevention or treatment comprising a fusion peptide in which a peptide represented by the amino acid sequence of No. 3 is bound to PTH represented by SEQ ID No. 4 or 5, or a fragment thereof. The fusion peptide of the present invention can selectively bind to the skeleton and increase the effect of PTH, increase the half-life and reduce the number of administrations. The fusion peptide according to the present invention can be used as a pharmaceutical composition for osteoporosis therapeutic agent and fracture therapeutic agent in the form of subcutaneous injection or intravenous injection, and can be used in combination with a medical device for tissue repair to increase the formation of bone tissue. it can. Also, when bonding to the surface of a dental and orthopedic medical device, it is possible to increase the safety of transplantation of the medical device by increasing the osseointegration of the medical device and new bone. [Selection] Figure 1本発明は副甲状線ホルモン（ｐａｒａｔｈｙｒｏｉｄ ｈｏｒｍｏｎｅ、ＰＴＨ）又はその切片に骨組職選択性ペプチドが結合されている融合ペプチドを有効成分として含む骨疾患予防又は治療用薬学組成物に関し、より詳しくは、配列番号３のアミノ酸配列で表示されるペプチドを配列番号４又は５で表示されるＰＴＨ又はその切片に結合させた融合ペプチドを含む骨疾患予防又は治療用薬学組成物及び生体材料に関する。本発明の融合ペプチドは、骨組職に選択的に結合してＰＴＨの効果を増加させ、半減期を増加させて投与回数を減少させることができる。本発明による融合ペプチドは皮下注射又は静脈注射形態の骨粗鬆症治療剤、骨折治療剤に使う薬学組成物として用いることができ、組職修復用医療機器と併用して骨組職の形成を増加させることができる。また、歯科及び整形外科用医療機器の表面に結合させる場合、医療機器と新生骨の融合（ｏｓｓｅｏｉｎｔｅｇｒａｔｉｏｎ）を増加させて医療機器の移植安全性を増加させることができる。【選択図】 図１
